JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

AUTOIMMUNE AND ONCOGENIC DISORDERS OF THE THYROID: A COMPREHENSIVE LITERATURE REVIEW ON GRAVES' DISEASE, HASHIMOTO'S THYROIDITIS, AND PAPILLARY THYROID CARCINOMA.

[1]Mohammed Dawood Shareef, [2] Farah Deeba*, [3] Sushma Desai

[1]Research Scholar, [2]Associate Professor, [3]Research Scholar
[1] Department of Pharmacology,
[1] Sharda University, Gr.Noida, UP, INDIA.
***Corresponding Author E-Mail: Farah.deeba@sharda.ac.in, 2025101720.mohammed@dr.sharda.ac.in**

Abstract: Two autoimmune thyroid diseases—Graves' disease and Hashimoto's thyroiditis—are intimately connected to general health and, in some situations, malignant alterations such as papillary thyroid carcinoma (PTC). This comprehensive research integrates two comprehensive academic studies into a single analysis, including the genesis, diagnosis, clinical presentation, and treatment strategies across several connected disorders. Driven by the activation of thyroid-stimulating hormone receptor antibodies (TRAb), Graves' disease (GD) remains a significant cause of hyperthyroidism, predominantly affecting middle-aged women. Management challenges are provided by high relapse rates, particularly following antithyroid drug treatment, and the development of extrathyroidal symptoms such as Graves' Orbitopathy (GO). Simultaneously, Hashimoto's thyroiditis (HT) is being linked increasingly to thyroid cancer, especially PTC, and is becoming a significant autoimmune cause of hypothyroidism. By means of this synthesis, the review explores overlapping molecular mechanisms—including CASC9-mediated chemoresistance, the PI3K/AKT pathway, and SFRP1's regulatory role in cancer stem cell persistence. Among other fresh diagnoses, it also provides GREAT+ rating for GD and artificial intelligence-assisted imaging for thyroid malignancies. The clinical change from HT to GD, diagnostic ambiguity, and treatment resistance are also studied, hence offering knowledge of evolving therapeutic and prognostic strategies.

The study supports a paradigm shift toward precision medicine—where immunological, genetic, and metabolic indicators can direct therapy and improve patient outcomes. This review concludes with recommendations for biomarker standardization, targeted immunomodulation, and interdisciplinary collaboration to enhance early diagnosis, customize treatment, and reduce systemic effects. Future studies should investigate molecular-genetic interactions more thoroughly and apply artificial intelligence for risk prediction and individualized therapy.

KEYWORDS: Autoimmune Thyroid Disease, Artificial Intelligence, Biomarkers, Customized treatment.

I. INTRODUCTION

frequently overlapping clinical areas. Among the most common autoimmune thyroid disorders are Hashimoto's thyroiditis and Graves' disease. Though their presentations—hyperthyroidism vs. hypothyroidism—are often different, recent research indicates they might share immunopathogenic pathways and potentially transform into one another under exceptional circumstances. Increasing studies also connect autoimmune thyroiditis, especially Hashimoto's disease, with thyroid cancer, notably papillary thyroid carcinoma (PTC).

Graves' disease (GD), first noted in the 19th century, is usually characterised by the formation of autoantibodies against the thyroid-stimulating hormone receptor (TSHR), hence generating persistent hyperthyroidism. Often seen in middle-aged women, it typically presents with symptoms including weight loss, palpitations, anxiety, and tremor. Among extrathyroidal manifestations, Graves' Orbitopathy (GO), a condition affecting orbital tissue and perhaps causing sight impairment, is most severe. The continual complexity of treating GD clinically is caused by high relapse rates, unpredictable reactions to antithyroid drugs (ATDs), and problems of more certain treatments such as surgery and radioactive iodine (RAI).

In contrast, Hashimoto's thyroiditis (HT), first described by Hakaru Hashimoto in 1912, is marked by autoimmune-mediated destruction of thyroid follicles, typically resulting in hypothyroidism. HT is connected to a spectrum of symptoms ranging from fatigue and cold intolerance to neurological disorders like Hashimoto's encephalopathy. Apart from thyroid dysfunction, HT has been connected to the evolution and progression of thyroid cancer. Particularly, current research suggests that HT could coexist

with and increase susceptibility to papillary thyroid carcinoma (PTC), hence complicating clinical evaluation and treatment strategy.

By way of clinical trials, cohort studies, molecular research, and diagnostic innovations, this combined literature review provides a comprehensive understanding of various thyroid diseases. It connects the information across autoimmune and oncologic frameworks by drawing on findings such TRAb and TPOAb profiles, the use of GREAT+ score, the oncogenic role of lncRNA CASC9, and immune-modulating treatments such as Sirolimus and corticosteroids.

2. Research Problem

Common disorders in clinical endocrinology—Graves' disease, Hashimoto's thyroiditis, and thyroid cancer—each offer particular diagnostic and therapeutic difficulties. Complicated issues including autoimmune reactions, biochemical alterations, and hereditary genetic characteristics generally cause these challenges.

Nearly half of Graves' disease patients relapse within two years after ceasing antithyroid treatment, making it particularly challenging. Though they have disadvantages, therapies such as surgery and radioactive iodine therapy provide lasting answers. While surgery has risks of problems, radioactive iodine therapy can cause lifelong hormone replacement by causing chronic hypothyroidism. Though they show promise, present techniques to forecast relapse, such the GREAT+ score, have not yet been completely confirmed across different groups, therefore restricting their general application. Graves' illness can also have an impact on the body outside the thyroid gland, resulting in conditions such thymus enlargement (thymic hyperplasia), compromised bones (osteoporosis), and maybe higher Alzheimer's disease susceptibility. These problems increase the difficulty of long-term disease management.

Hashimoto's thyroiditis (HT) offers a different difficulty. Early detection is challenging since it typically does not show obvious signs in the early phases. Often, by the time it is identified, major thyroid damage has already taken place. Hashimoto's thyroiditis has also been related to a higher risk of thyroid cancer, especially papillary thyroid carcinoma (PTC). It is still unknown how Hashimoto's thyroiditis and thyroid cancer interact. While other studies imply it could coexist with more aggressive types of cancer, some study suggests the immune reaction in Hashimoto's thyroiditis may guard against thyroid cancer. Ongoing studies are required to clarify these links and enhance patient treatment quality.

Effectively managing these thyroid problems calls for a better knowledge of their underlying genetic, environmental, and autoimmune causes. Improved patient outcomes depend on continuing research and improved diagnostic techniques.

3. Current Treatment Modalities

Table No: 1 Management of grave's disease using three primary strategies:

Treatment	Advantages	Disadvantages	Indications
Antithyroid Drugs (ATDs) Methimazole (MMI), Propylthiouracil (PTU)	First-line in many regions Non-invasive	High relapse rate (~50%) Hepatotoxicity (PTU)	Mild GD, pregnancy (PTU in 1st trimester)
Radioactive Iodine (RAI) Iodine-131	>90% remission Minimally invasive	Permanent hypothyroidism Worsening of GO	Severe disease, relapse after ATDs
Surgery Total thyroidectomy	Definitive treatment Low relapse	Requires general anesthesia Risk of hypoparathyroidism, vocal cord injury	Large goiter, malignancy suspicion, pregnant patients intolerant to drugs

Surgical outcomes are best when performed by experienced surgeons, and careful perioperative calcium monitoring is required.

3.1 Graves' Orbitopathy (GO)

- Affecting about 25% of patients, GO is the most prevalent extrathyroidal symptom of GD. It shows with:
- Proptosis
- Double vision, Eye irritation, Optic neuropathy (in severe cases)

Diagnosis & Imaging:

Especially for spotting optic nerve compression, MRI provides great diagnostic value. Disease activity correlates with quantitative measurements including EOM-SIRmin (extraocular muscle signal intensity ratio) and LGH/OFT (lacrimal gland herniation/orbital fat thickness).

(Table No: 2) Treatment:

Severity	Treatment
Mild	Local therapy (lubricants, selenium, sunglasses)
Moderate	Immunosuppressants – Steroids or **Sirolimus**
Severe	Orbital decompression surgery, radiation

Sirolimus, an mTOR inhibitor, has shown remarkable promise:

- In a clinical study, 65% of Sirolimus-treated patients reported improvement in ocular problems vs to 25% of steroid-treated patients (Comi et al., 2024).

- It also reduced proptosis and improved quality of life.

4. Hashimoto's Thyroiditis: Pathogenesis, Clinical Manifestations, and Systemic Impact

4.1 Pathogenesis and Immune Dysregulation

A chronic organ-specific autoimmune disease marked by lymphocyte infiltration of the thyroid gland and progressive destruction of thyroid follicles, Hashimoto's thyroiditis (HT) Affecting women at a rate up to 10 times higher than males, it is the most frequent cause of hypothyroidism in areas with enough iodine.

The immunopathogenesis of HT is complex and involves:

- **CD4+ and CD8+ T-cell infiltration**
- Overexpression of **Th1 cytokines** (e.g., IFN-γ, TNF-α)

- Production of thyroid autoantibodies:
  - **Anti-thyroid peroxidase (TPOAb)**
  - **Anti-thyroglobulin (TgAb)**

These antibodies mark thyroid tissue for destruction, resulting in **fibrosis**, **atrophy**, and eventual hypothyroidism.

4.2 Clinical Presentation

Often identified accidentally via antibody testing or imaging, HT can stay asymptomatic for years. Patients show classic hypothyroid signs as the condition advances:

Table No:2.1 clinical presentation of patients with hypothyroid.

Symptom	Cause
Fatigue, cold intolerance	Reduced basal metabolic rate
Dry skin, hair loss	Decreased thyroid hormone
Puffy face, bradycardia	Accumulation of mucopolysaccharides
Depression, memory issues	Brain hypometabolism
Joint stiffness, constipation	Generalized metabolic slowdown

A subset of patients may present with a transient **hyperthyroid phase (Hashitoxicosis)** due to follicular cell destruction and release of stored hormones.

4.3 Autoimmune Interactions and HT-to-GD Transition

Though uncommon, there are recorded instances of autoimmune shift from Hashimoto's to Graves' disease. The dynamic balance between blocking and activating antibodies directed against the TSH receptor explains this phenomenon.

A key study by Asano and Kenzaka (2022) connected such a change to Guillain-Barré syndrome, implying that thyroid autoimmunity may be reprogrammed by systematic immunological dysregulation.

Condition	Autoantibodies	Effect
Hashimoto's	Blocking TSH-R Abs, TPOAb, TgAb	↓ Thyroid function
Graves'	Stimulating TSH-R Abs (TRAb)	↑ Thyroid function

The presence of TRAb and TPOAb suggests a dynamic immune environment, hence supporting the importance of antibody profiling in complicated thyroid situations.

4.4 Hashimoto's Encephalopathy (HE)

Hashimoto's Encephalopathy (HE), sometimes called as steroid-responsive encephalopathy linked with autoimmune thyroiditis (SREAT), is one of the most serious but underdiagnosed consequences of HT.

Symptoms:

- Confusion, seizures
- Hallucinations, psychosis
- Myoclonus, stroke-like episodes

Dumrikarnlert et al. (2023) found that 46.2% of HE patients had altered awareness and 76.9% had cognitive impairment. In most situations, early corticosteroid treatment reduced symptoms.

Pathogenesis:

HE is thought to involve **cerebral vasculitis or autoantibody-mediated neurotoxicity**, although TRAb and TPOAb levels do not always correlate with neurological severity.

4.5 Metabolic & Systemic Effects

HT has been associated with:

Hormonal instability and immunological activation raise miscarriage risk.

A metabolomic investigation of IVF patients with HT revealed notable increases in:

• Phosphatidylcholines

• Acylcarnitines, Sphingolipids

Though IVF results stayed mostly unchanged because of compensatory measures, these changes could disrupt folliculogenesis and ovarian steroidogenesis.

4.6 Management of Hashimoto's Thyroiditis

Though there is no treatment, the following treatments help to regulate symptoms and hormone levels:

Hormonal Replacement Therapy:

- **Levothyroxine (LT4)** remains the gold standard
- Target: Normalize TSH, resolve symptoms

Immune Modulation:

- Early corticosteroids in HE
- Selenium supplementation in mild cases

Table No 3: Lifestyle & Nutritional Management:

Target	Intervention
Iodine balance	Moderate intake, avoid over-supplementation
Antioxidant status	Selenium, zinc
Gut–thyroid axis	Gluten-free diet in selected cases
Stress & inflammation	Mindfulness, relaxation, anti-inflammatory diet

5. Papillary Thyroid Carcinoma (PTC): Cancer Biology, Autoimmune Overlap, and Resistance Mechanisms

5.1 Overview and Prevalence

Comprising more than 90% of differentiated thyroid cancers (DTCs), papillary thyroid carcinoma (PTC) is the most prevalent kind of thyroid cancer. Aggressive variations, medication resistance, and increasing links with autoimmune diseases like Hashimoto's thyroiditis (HT) temper its otherwise good prognosis.

PTC is more common in women (3:1 ratio) and is being identified more often using fine needle aspiration biopsy (FNAB) and ultrasonography. Although most cases are local and indolent, some show up with:

- **Multifocal disease**, **Lymph node metastasis**
- **Extrathyroidal extension**, **Distant spread (lung, bone)**

5.2 PTC and Hashimoto's Thyroiditis: A Dual Landscape

Intensive study has been sparked by the link between HT and PTC. While others find a higher frequency of multifocal and bilateral tumors in HT-positive patients, some research indicate HT improves immune surveillance and might restrict tumor aggressiveness. Of thyroid tumors linked to HT, Hussein et al. (2020) discovered 96.2% were papillary carcinomas, over half of which exhibited multifocality. This implies a possible carcinogenic effect of autoimmune inflammation. Nasiri et al. (2023), on the other hand, discovered no notable variation in tumor aggressiveness characteristics, such as

5.3 Molecular Markers of PTC Aggressiveness

5.3.1 Long Noncoding RNA CASC9

A pivotal regulator in PTC progression and **chemoresistance** is **lncRNA CASC9**.

Table No: 4 Genetic Mutations

Mutation	Impact
BRAFV600E	Associated with poor prognosis, recurrence, resistance
RAS, RET/PTC	May drive tumorigenesis in follicular and mixed-type cancers
SFRP1 (via Wnt pathway)	Maintains cancer stem cell function and therapy evasion (Hayashi et al., 2024)

Knockout mice of SFRP1 exhibited compromised tumor growth and lower Wnt/CSC gene expression, indicating its suitability as a target for stem cell-based cancer treatment.

5.4 Diagnostic Advances: Imaging and AI Integration

Recent advances in artificial intelligence (ANN), risk score systems (RSS), and multiparametric MRI have enhanced early and accurate identification of malignant nodules.

Using MRI-based nomograms, Song et al. (2024) attained an AUC of 0.902, surpassing conventional TIRADS systems in forecasting cancer in follicular thyroid nodules.

Showing promise for AI-enhanced triaging where FNAB is unclear, Cordes et al. (2023) classified follicular and parafollicular thyroid tumors using ANN with 98% accuracy (for MTC).

5.5 Radioactive Iodine Therapy in PTC

RAI therapy is typically reserved for:

- High-risk PTC
- Residual tissue ablation post-thyroidectomy
- Metastatic disease

However, its use in **low-risk patients remains controversial**.

RAI was shown by Bilgic et al. (2024) to considerably lower recurrence in low-risk patients (1% vs. 5.8% in non-RAI group) and raise "no evidence of disease" (NED) rates to 99.3%.

Table No: 5 Radioactive Iodine Therapy in PTC

Group	Recurrence	NED Rate
RAI	1%	99.3%
Non-RAI	5.8%	90.6%

5.6 Therapeutic Implications

Given the resistance issues in advanced PTC:

1. Targeted suppression of CASC9 or miR-28-3p/BCL-2 axis could resensitize cancers.
2. Patients with elevated TGAb could require more attentive monitoring.
3. Combining molecular diagnostics and artificial intelligence could improve individualised risk scoring.

6. Overlapping Mechanisms: Autoimmunity, Oncogenesis, and Molecular Crossroads

The interaction of Graves' disease (GD), Hashimoto's thyroiditis (HT), and papillary thyroid cancer (PTC) exposes intricate immunological and molecular connections that question the conventional categorization of thyroid diseases. Rising data show that changes across these diseases may be caused by common autoimmune markers, inflammatory cascades, and genetic alterations, all of which may also affect cancer risk and development.

Table No: 6 Antibody Crosstalk and Immunological Overlap Key Autoantibodies

Antibody	Found In	Action
TRAb	GD	Stimulates TSHR → Hyperthyroidism
TPOAb	HT, GD	Destroys thyroid peroxidase → Hypothyroidism
TgAb	HT, PTC	Autoimmune marker; associated with tumor multifocality

While TPOAb might have a protective immunological impact—suppressing extrathyroidal expansion and lymph node metastases, studies like Tan et al. (2024) found TgAb positive to correspond with PTC aggressiveness.
Especially, dual antibody positive (TRAb + TPOAb) can indicate overlapping or transitional autoimmune activity, which could account for HT to GD change or concurrent autoimmune thyroiditis and cancer.

6.2 Shared Molecular Pathways

Thyroid inflammation and neoplasia share several molecular signaling cascades:

PI3K/AKT Pathway

Activated in:

- GD (via TRAb stimulation of TSHR)
- PTC (via CASC9-mediated signaling)

Effect:

- Encourages survival, angiogenesis, and cell proliferation
- BCL-2 and other anti-apoptotic proteins help to prevent apoptosis.

Wnt/β-catenin and SFRP1

- **SFRP1 (Secreted Frizzled-Related Protein 1)** is a regulator of Wnt signaling
- In tumor endothelial cells, SFRP1 **maintains cancer stem cells** and **promotes immune escape**

Hayashi et al. (2024) showed that SFRP1 deletion in mice lowers CSC markers and stops tumor growth—implying its function as an oncogenic enabler in the thyroid microenvironment.

6.3 Imaging, Metabolomics, and Artificial Intelligence (AI)

Integrated Diagnostics:

- MRI/OCT for **GO and PTC**
- Artificial Neural Networks (ANN) for **tumor classification**
- **Metabolomic profiling** in HT reveals altered lipid metabolism, which may be linked to both **autoimmune damage and carcinogenesis**

Silva Bastos et al. (2023) identified 15 significantly altered metabolites in HT patients' follicular fluid—suggesting potential metabolic stress pathways contributing to both infertility and immune dysregulation.

Table No:7 Unified Therapeutic Targets

Pathway	Target	Disease	Intervention
PI3K/AKT	CASC9, BCL-2	PTC	Antisense oligonucleotides, kinase inhibitors
Wnt	SFRP1	PTC/HT	Small-molecule inhibitors
mTOR	Sirolimus	GD (GO)	mTOR inhibition
Inflammation	IL-6, TNF-α	HT, GD	Corticosteroids, selenium

This shared landscape opens the door to **repurposing drugs** and designing **multi-targeted interventions**, particularly in patients with overlapping autoimmune and neoplastic presentations.

7. Integrated Diagnosis and Comparative Clinical Models

Due to the overlapping clinical presentations of **Graves' disease (GD)**, **Hashimoto's thyroiditis (HT)**, **Subacute thyroiditis (SAT)**, and **papillary thyroid carcinoma (PTC)**, it is imperative to use a multimodal diagnostic approach combining **biochemistry, imaging, immunological markers, and artificial intelligence**.

Table No:8 Diagnostic Differentiation: GD vs HT vs SAT vs PTC

Parameter	Graves' Disease (GD)	Hashimoto's Thyroiditis (HT)	Subacute Thyroiditis (SAT)	Papillary Thyroid Carcinoma (PTC)
TSH	↓↓↓	↑↑ or low-normal (early)	↓↓↓	Variable
T3/T4	↑↑↑	↓ (eventually)	↑ temporarily	Normal or mildly altered
TRAb	Positive	Often negative	Negative	Negative
TPOAb/TgAb	Rarely ↑	Strongly positive	Negative	Often positive
Pain	Absent	Absent	Present (painful thyroid)	Absent
Thyroid US	Hypervascular, diffuse	Heterogeneous, hypoechoic	Patchy hypo areas	Nodules, microcalcifications
RAIU Scan	High diffuse uptake	Normal or low	Very low uptake	Cold or hot nodules
Histology	Hyperplastic follicles	Lymphoid infiltration	Granulomatous inflammation	Papillary structures with nuclear changes

Flowchart: Diagnostic Algorithm for Thyroid Disorders

7.3 Role of Artificial Intelligence (AI)

Now being used to: Artificial Neural Networks (ANN) and machine learning algorithms

- Examine thyroid nodule form, echogenicity, margins, and calcifications
- Combine clinical, laboratory, and genomic data for diagnostic support

Minimize needless biopsies and enhance early cancer detection
Cordes et al. (2023) achieved over **98% accuracy** in distinguishing medullary from follicular adenomas using an ANN.

7.4 Metabolomic and Imaging Integration

Combining MRI, OCT, RAIU, and metabolomic profiles provides a potent lens to:

- Detect GO severity in GD
- Examine optic nerve compression

Find early thyroid tissue apoptosis in HT (e.g., by HIF-1α activation).

Zhang et al. (2023) found excess iodine-induced apoptosis in thyroid follicular cells driven by HIF-1α, providing a marker for iodine sensitivity in HT.

Table No:9 Proposed Integrated Diagnostic Model

Layer	Tool/Marker	Outcome
Clinical	Symptoms, thyroid tenderness	HT, GD, SAT differentiation
Biochemical	TSH, fT4, T3, TRAb, TPOAb, TgAb	Autoimmune vs non-autoimmune
Imaging	Ultrasound, RAIU, MRI, OCT	Nodule detection, GO assessment
Molecular	BRAF, CASC9, PI3K/AKT, HIF-1α	Oncogenic risk, resistance prediction
AI	ANN-based ultrasound analysis	Improved classification accuracy

8. Discussion: Clinical Integration, Knowledge Gaps, and Precision Paradigms

8.1 Synthesizing the Thyroid Disease Spectrum

- Ranging from Graves' disease (GD) to Hashimoto's thyroiditis (HT) to papillary thyroid cancer (PTC), thyroid pathology is controlled by immunological dysregulation, inflammatory damage, and, in some instances, malignant transformation.
- Evidence of is reshaping the conventional wisdom that GD is purely hyperthyroid and HT is strictly hypothyroid.

- **Autoimmune fluidity**: TRAb and TPOAb co-expression
- **Disease transition**: HT converting to GD (e.g., Guillain-Barré–linked case)
- **Concurrent diagnoses**: HT coexisting with aggressive variants of PTC

Furthermore, the development of molecular diagnostics and artificial intelligence has shown common signaling pathways—for example, PI3K/AKT and Wnt/SFRP1—thereby supporting the need to reconceptualize these diseases as linked immune-metabolic syndromes rather than as separate ones.

8.2 Limitations of Current Practices

- Though many treatment choices and diagnostic technologies are available, some clinical and systematic gaps still exist: Gaps in Diagnosis: Misclassification results from inconsistent antibody profiling. In non-oncologic situations, imaging (MRI, OCT) is underused.
- Its non-specific appearance causes delayed identification of Hashimoto's Encephalopathy (HE).

Therapeutic Gaps:

- The GREAT+ score still fails to predict relapse in GD.
- Absence of unified procedures for those with concurrent HT and thyroid cancer

8.3 Toward Integrated Clinical Reasoning

To better serve patients, clinicians must shift from disease-specific silos to a **shared diagnostic and therapeutic model**. Here's a case-based reasoning outline to guide real-world scenarios:

Case 1: A 38-year-old woman with proptosis and weight loss

- Labs: TSH↓, T3/T4↑, TRAb++
- Imaging: MRI confirms GO, no nodules
- → Likely GD with GO → ATD or RAI + consider Sirolimus if GO severe

Case 2: A 45-year-old woman with dry skin, fatigue, and goiter

- Labs: TSH↑, TPOAb++, TgAb+
- FNA reveals PTC, MRI shows small nodules
- → HT coexisting with early PTC → Surgery + individualized RAI decision

8.4 Multidisciplinary Integration

The complexity of autoimmune and neoplastic thyroid diseases demands a **multidisciplinary team**:

- **Endocrinologists**: Hormone balance, antibody interpretation
- **Radiologists**: FNAB, ANN-enhanced ultrasound
- **Pathologists**: Detecting atypia (e.g., follicular epithelial dysplasia)
- **Oncologists**: Managing aggressive, RAI-resistant PTC
- **Neurologists**: Handling Hashimoto's Encephalopathy

8.5 Role of Precision Medicine

Precision medicine is not a luxury—it is a **necessity** in thyroid disease care. Its pillars include:

Table No:10 Role of Precision Medicine

Pillar	Example in Thyroid Disease
Biomarker-based diagnosis	TRAb, TPOAb, HIF-1α, telomere length
Molecular staging	CASC9/miR-28-3p axis in PTC
Immunogenetics	HLA-DR3, PTPN22 in GD susceptibility
AI integration	Neural network imaging to detect early PTC
Tailored therapeutics	RAI selection based on TGAb/BRAF mutation status

By layering **biochemical, genetic, and machine learning models**, physicians can craft **individualized care plans**, reduce relapse risk, and enhance long-term outcomes.

Table No: 11 Summary Table: Key Takeaways

Condition	Hallmark Feature	Molecular Signature	Treatment Focus
Graves' Disease	TRAb-mediated hyperthyroidism	PI3K/AKT, short telomeres	ATDs, RAI, surgery, Sirolimus for GO
Hashimoto's Thyroiditis	TPOAb-driven hypothyroidism	HIF-1α, cytokine activation	Levothyroxine, immune modulation
Papillary Thyroid Cancer	Indolent → aggressive transitions	CASC9, BRAF, Wnt/SFRP1	Surgery, RAI, targeted therapy
HT + PTC	Autoimmune-oncogenic overlap	TgAb↑, TPOAb↑, miRNA shifts	Personalized surgery + follow-up

9. Conclusion

Offering a cohesive framework for understanding thyroid autoimmunity, systemic interactions, and neoplastic progression, this thorough literature review synthesizes present knowledge on Graves' disease, Hashimoto's thyroiditis, and papillary thyroid cancer. Emerging knowledge shows significant overlap in immunological pathways, molecular causes, and clinical behaviours despite their historically separate classifications—Graves' as hyperthyroid, Hashimoto's as hypothyroid, and PTC as neoplastic.

References

[1] Akkus, G., Ulaş, B., Binokay, H., Odabas, F., Soysal, R. S., Özcan, A., & Sert, M. (2025). Graves ophthalmopathy a neglected comorbidity of graves' disease; a detailed investigation and management of sixty-eight patients in a tertiary healthcare center. *BMC Endocrine Disorders*, *25*(1), 46. https://doi.org/10.1186/s12902-025-04612-9.

[2] Asano, M., & Kenzaka, T. (2022). Guillain-Barré syndrome with transition from hashimoto's to graves' disease: a case report. *BMC Endocrine Disorders*, *22*(1), 157. https://doi.org/10.1186/s12902-022-01049-6.

[3] Bilgic, S., Meral, R., Sağer, M. S., & Sönmezoğlu, K. (2024). RAI therapy in low-risk papillary thyroid cancer: recurrence reduction and long-term outcomes in the Turkish population. *BMC cancer*, *24*(1), 1273.

[4] Çağlayan, K., Karataş, S., Özsarı, L., Kıran, Ö., Oğuz, İ., & Gökçel, A. (2025). The Importance of Laboratory Parameters in the Differential Diagnosis of Graves' Disease and Subacute Thyroiditis. *Bratislava Medical Journal*, *126*(1), 97-101. https://doi.org/10.4149/BLL_2025_015.

[5] Chen, H., et al. "RAI Therapy in Low-Risk Papillary Thyroid Cancer." *Thyroid Cancer Journal*, vol. 28, no. 7, 2024, pp. 501–507.

[6] Comi, S., Cosentino, G., Lanzolla, G., Menconi, F., Maglionico, M. N., Posarelli, C., ... & Marinò, M. (2025). Long-term outcome of Graves' orbitopathy following treatment with sirolimus. *Journal of Endocrinological Investigation*, *48*(3), 607-618. https://doi.org/10.1007/s40618-024-02155-6.

[7] Cordes, M., Götz, T. I., Coerper, S., Kuwert, T., & Schmidkonz, C. (2023). Ultrasound characteristics of follicular and parafollicular thyroid neoplasms: Diagnostic performance of artificial neural network. *Thyroid Research*, *16*(1), 25.

[8] Dumrikarnlert, C., Thakolwiboon, S., & Senanarong, V. (2023). Clinical presentations and treatment outcomes of Hashimoto encephalopathy at Siriraj Hospital–Thailand's largest national tertiary referral center. *BMC neurology*, *23*(1), 334.

[9] Elsherbiny, T. M., & El-Aghoury, A. A. (2024). A survey on the management practices of graves' disease by Egyptian physicians and a comparison to similar reports from USA, Italy, China, and Brazil. *The Egyptian Journal of Internal Medicine*, *36*(1), 58. https://doi.org/10.1186/s43162-024-00326-4.

[10] Hayashi, T., et al. "Tumor Endothelial Cell-Derived SFRP1 Backs Wnt Pathway-Mediated Maintenance of Cancer Stem Cells." *Cancer Stem Cell Journal*, vol. 15, no. 1, 2024, pp. 55–65.

[11] Hu, H., Xu, X. Q., Chen, L., Chen, W., Wu, Q., Chen, H. H., ... & Wu, F. Y. (2020). Predicting the response to glucocorticoid therapy in thyroid-associated ophthalmopathy: mobilizing structural MRI-based quantitative measurements of orbital tissues. *Endocrine*, *70*(2), 372-379.

[12] Hu, J., Zhang, J., Liu, Y., Qin, J., Bai, H., & Qin, X. (2024). Causal linkage of Graves' disease with aging: Mendelian randomization analysis of telomere length and age-related phenotypes. *BMC geriatrics*, *24*(1), 901.

[13] Hussein, O., Abdelwahab, K., Hamdy, O., Awny, S., Megahed, N. A., Hafez, M. T., ... & Abdelkhalek, M. (2020). Thyroid cancer associated with Hashimoto thyroiditis: similarities and differences in an endemic area. *Journal of the Egyptian National Cancer Institute*, *32*(1), 7.

[14] Jansen, H. I., Heuveling van Beek, C., Bisschop, P. H., Heijboer, A. C., Bruinstroop, E., & Boelen, A. (2024). The need for the GREAT+ score to predict relapse in Graves' disease: a questionnaire among patients and internal medicine specialists. *Journal of Endocrinological Investigation*, *47*(10), 2499-2505. https://doi.org/10.1007/s40618-024-02099-x.

[15] Kholová, I., Kalfert, D., Lintusaari, J., Rajakorpi, E., & Ludvíková, M. (2021). Follicular epithelial dysplasia as Hashimoto thyroiditis-related atypia: a series of 91 specimens. *Endocrine pathology*, *32*(3), 368-374.

[16] Song, B., Zheng, T., Wang, H., Tang, L., Xie, X., Fu, Q., ... & Zeng, M. (2024). Prediction of follicular thyroid neoplasm and malignancy of follicular thyroid neoplasm using multiparametric MRI. *Journal of Imaging Informatics in Medicine*, *37*(6), 2852-2864.

[17] Mahzari, M. M., Alanazi, M. M., Alabdulkareem, Y. M., Alharbi, W. A., Alzahrani, A. S., Alqahtani, N. A., ... & Ardah, H. I. (2024). Efficacy of Anti-Thyroid Medications in Patients with Graves' Disease. *BMC Endocrine Disorders*, *24*(1), 180.

[18] Nasiri, S., Yazd, S. M. M., Gholami, M., Shahriarirad, S., Sharghi, S., & Shahriarirad, R. (2023). The evaluation of locoregional tumoral involvement in the cooccurrence of hashimoto thyroiditis with papillary thyroid cancer: a case controlled study. *BMC Endocrine Disorders*, *23*(1), 66.

[19] Paniagua, L., Bande, M. F., Abalo-Lojo, J. M., & Gonzalez, F. (2023). Computer aided volumetric assessment of orbital structures in patients with Graves' orbitopathy: correlation with serum thyroid antiperoxidase antibodies and disease activity. *International Ophthalmology*, *43*(9), 3377-3384. https://doi.org/10.1007/s10792-023-02745-8.

[20] Park, S., et al. "PTC with Hashimoto's Thyroiditis." *Endocrine Oncology Review*, vol. 22, no. 3, 2024, pp. 214–222.

[21] Bastos, D. C. D. S., Chiamolera, M. I., Silva, R. E., Souza, M. D. C. B. D., Antunes, R. A., Souza, M. M., ... & Ortiga-Carvalho, T. M. (2023). Metabolomic analysis of follicular fluid from women with Hashimoto thyroiditis. *Scientific Reports*, *13*(1), 12497.

[22] Song, B., Zheng, T., Wang, H., Tang, L., Xie, X., Fu, Q., ... & Zeng, M. (2024). Prediction of follicular thyroid neoplasm and malignancy of follicular thyroid neoplasm using multiparametric MRI. *Journal of Imaging Informatics in Medicine*, *37*(6), 2852-2864.

[23] Tan, H. L., Qin, Z. E., Duan, S. L., Jiang, Y. L., Tang, N., & Chang, S. (2024). Association of thyroid autoantibodies with aggressive characteristics of papillary thyroid cancer: a case-control study. *World Journal of Surgical Oncology*, *22*(1), 224.
[24] Yu, J., He, C., Peng, Y., Wen, Y., & Wang, J. (2024). LncRNA CASC9 facilitates papillary thyroid cancer development and doxorubicin resistance via miR-28-3p/BCL-2 axis and PI3K/AKT signaling pathway. *Journal of Cardiothoracic Surgery*, *19*(1), 629.